This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Earnings Estimates Moving Higher for Harrow (HROW): Time to Buy?
by Zacks Equity Research
Harrow (HROW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Teladoc (TDOC) Falls 8.1% Despite Upbeat Revenue Guidance
by Zacks Equity Research
Teladoc Health (TDOC) expects revenues to rise to more than $4 billion in 2024.
Harrow Health (HROW) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of 66.67% and 8.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Harrow Health (HROW) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of 15.38% and 16.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Harrow Health (HROW) in Q2 Earnings?
by Zacks Equity Research
Harrow Health (HROW) Q2 results are likely to reflect growth coming from the launch of Visionology, the company's direct-to-consumer eyecare platform.
Analysts Estimate Harrow Health (HROW) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harrow Health (HROW) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Harrow Health (HROW) closed at $8.97, marking a +0.56% move from the previous day.
Is Harrow Health (HROW) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (HROW) Outperforming Other Medical Stocks This Year?
Down 14% in 4 Weeks, Here's Why You Should You Buy the Dip in Harrow (HROW)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Harrow (HROW) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Avantor, Inc. (AVTR) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Avantor, Inc. (AVTR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Bet on 4 Low-Beta MedTech Stocks to Ride the Choppy Market
by Riya Anand
Stocks like Henry Schein (HSIC), BellRing Brands (BRBR), Harrow Health (HROW) and West Pharmaceuticals Services (WST) are solid low-beta picks with strong fundamentals.
Harrow (HROW) Surges 12%: Is This an Indication of Further Gains?
by Zacks Equity Research
Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Will Harrow Health (HROW) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HealthEquity (HQY) Enhances Commuter Offering With New Buyout
by Zacks Equity Research
HealthEquity's (HQY) buyout of Luum will strengthen the former's potential for new hybrid workplace as well as provide safe and affordable commuting options to employees.
Harrow Health (HROW) Lags Q4 Earnings Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of -50.00% and 0.73%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Harrow Health (HROW) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights: Apollo Medical, bioMerieux, CareDx and Harrow Health
by Zacks Equity Research
Zacks Industry Outlook Highlights: Apollo Medical, bioMerieux, CareDx and Harrow Health
4 Top Medical Services Stocks to Beat COVID-19 Resurgence Crisis
by Urmimala Biswas
Despite the severe challenges posed by the COVID-19 pandemic, higher demand for telemedicine, digital influence and AI is likely to lend support to the Zacks Medical - Service industry. AMEH, BMXMF, CDNA and HROW are well positioned to gain.
Harrow Health (HROW) Looks Good: Stock Adds 9.1% in Session
by Zacks Equity Research
Harrow Health (HROW) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Harrow Health (HROW) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of 88.24% and 65.89%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Harrow Health (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harrow Health (HROW) Enters Oversold Territory
by Zacks Equity Research
Harrow Health has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Harrow Health's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Harrow Health.
Harrow Health's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Harrow Health.
Harrow Health (HROW) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of 80.00% and 36.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?